Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome.

Jacquemont S, Pacini L, Jønch AE, Cencelli G, Rozenberg I, He Y, D'Andrea L, Pedini G, Eldeeb M, Willemsen R, Gasparini F, Tassone F, Hagerman R, Gomez-Mancilla B, Bagni C.

Hum Mol Genet. 2018 Nov 1;27(21):3825. doi: 10.1093/hmg/ddy291. No abstract available.

2.

First-in-Man Intrathecal Application of Neurite Growth-Promoting Anti-Nogo-A Antibodies in Acute Spinal Cord Injury.

Kucher K, Johns D, Maier D, Abel R, Badke A, Baron H, Thietje R, Casha S, Meindl R, Gomez-Mancilla B, Pfister C, Rupp R, Weidner N, Mir A, Schwab ME, Curt A.

Neurorehabil Neural Repair. 2018 Jun;32(6-7):578-589. doi: 10.1177/1545968318776371. Epub 2018 Jun 5.

PMID:
29869587
3.

Protein synthesis levels are increased in a subset of individuals with fragile X syndrome.

Jacquemont S, Pacini L, Jønch AE, Cencelli G, Rozenberg I, He Y, D'Andrea L, Pedini G, Eldeeb M, Willemsen R, Gasparini F, Tassone F, Hagerman R, Gomez-Mancilla B, Bagni C.

Hum Mol Genet. 2018 Jun 15;27(12):2039-2051. doi: 10.1093/hmg/ddy099. Erratum in: Hum Mol Genet. 2018 Nov 1;27(21):3825.

4.

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome.

Berry-Kravis EM, Lindemann L, Jønch AE, Apostol G, Bear MF, Carpenter RL, Crawley JN, Curie A, Des Portes V, Hossain F, Gasparini F, Gomez-Mancilla B, Hessl D, Loth E, Scharf SH, Wang PP, Von Raison F, Hagerman R, Spooren W, Jacquemont S.

Nat Rev Drug Discov. 2018 Apr;17(4):280-299. doi: 10.1038/nrd.2017.221. Epub 2017 Dec 8. Review.

PMID:
29217836
5.

Deficient striatal adaptation in aminergic and glutamatergic neurotransmission is associated with tardive dyskinesia in non-human primates exposed to antipsychotic drugs.

Lévesque C, Hernandez G, Mahmoudi S, Calon F, Gasparini F, Gomez-Mancilla B, Blanchet PJ, Lévesque D.

Neuroscience. 2017 Oct 11;361:43-57. doi: 10.1016/j.neuroscience.2017.07.068. Epub 2017 Aug 5.

PMID:
28790021
6.

Mavoglurant Augmentation in OCD Patients Resistant to Selective Serotonin Reuptake Inhibitors: A Proof-of-Concept, Randomized, Placebo-Controlled, Phase 2 Study.

Rutrick D, Stein DJ, Subramanian G, Smith B, Fava M, Hasler G, Cha JH, Gasparini F, Donchev T, Ocwieja M, Johns D, Gomez-Mancilla B.

Adv Ther. 2017 Feb;34(2):524-541. doi: 10.1007/s12325-016-0468-5. Epub 2017 Jan 2.

PMID:
28044255
7.

CGG Repeat-Induced FMR1 Silencing Depends on the Expansion Size in Human iPSCs and Neurons Carrying Unmethylated Full Mutations.

Brykczynska U, Pecho-Vrieseling E, Thiemeyer A, Klein J, Fruh I, Doll T, Manneville C, Fuchs S, Iazeolla M, Beibel M, Roma G, Naumann U, Kelley N, Oakeley EJ, Mueller M, Gomez-Mancilla B, Bühler M, Tabolacci E, Chiurazzi P, Neri G, Bouwmeester T, Di Giorgio FP, Fodor BD.

Stem Cell Reports. 2016 Dec 13;7(6):1059-1071. doi: 10.1016/j.stemcr.2016.10.004. Epub 2016 Nov 10.

8.

Task-related fMRI responses to a nicotinic acetylcholine receptor partial agonist in schizophrenia: A randomized trial.

Barch DM, Marder SR, Harms MP, Jarskog LF, Buchanan RW, Cronenwett W, Chen LS, Weiss M, Maguire RP, Pezous N, Feuerbach D, Lopez-Lopez C, Johns DR, Behrje RB, Gomez-Mancilla B.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Nov 3;71:66-75. doi: 10.1016/j.pnpbp.2016.06.013. Epub 2016 Jun 28.

9.

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.

Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569. Epub 2016 Mar 15.

PMID:
26990766
10.

Reciprocal changes in DNA methylation and hydroxymethylation and a broad repressive epigenetic switch characterize FMR1 transcriptional silencing in fragile X syndrome.

Brasa S, Mueller A, Jacquemont S, Hahne F, Rozenberg I, Peters T, He Y, McCormack C, Gasparini F, Chibout SD, Grenet O, Moggs J, Gomez-Mancilla B, Terranova R.

Clin Epigenetics. 2016 Feb 5;8:15. doi: 10.1186/s13148-016-0181-x. eCollection 2016.

11.

Assessment of Cognitive Outcome Measures in Teenagers with 15q13.3 Microdeletion Syndrome.

Crutcher E, Ali M, Harrison J, Sovago J, Gomez-Mancilla B, Schaaf CP.

J Autism Dev Disord. 2016 Apr;46(4):1455-63. doi: 10.1007/s10803-015-2694-0.

12.

Characterization of brain mGluR5 binding in a pilot study of late-life major depressive disorder using positron emission tomography and [¹¹C]ABP688.

DeLorenzo C, Sovago J, Gardus J, Xu J, Yang J, Behrje R, Kumar JS, Devanand DP, Pelton GH, Mathis CA, Mason NS, Gomez-Mancilla B, Aizenstein H, Mann JJ, Parsey RV.

Transl Psychiatry. 2015 Dec 8;5:e693. doi: 10.1038/tp.2015.189.

13.

High-Throughput Screening Using iPSC-Derived Neuronal Progenitors to Identify Compounds Counteracting Epigenetic Gene Silencing in Fragile X Syndrome.

Kaufmann M, Schuffenhauer A, Fruh I, Klein J, Thiemeyer A, Rigo P, Gomez-Mancilla B, Heidinger-Millot V, Bouwmeester T, Schopfer U, Mueller M, Fodor BD, Cobos-Correa A.

J Biomol Screen. 2015 Oct;20(9):1101-11. doi: 10.1177/1087057115588287. Epub 2015 May 29.

PMID:
26024946
14.

A randomized, placebo-controlled trial of AFQ056 for the treatment of chorea in Huntington's disease.

Reilmann R, Rouzade-Dominguez ML, Saft C, Süssmuth SD, Priller J, Rosser A, Rickards H, Schöls L, Pezous N, Gasparini F, Johns D, Landwehrmeyer GB, Gomez-Mancilla B.

Mov Disord. 2015 Mar;30(3):427-31. doi: 10.1002/mds.26174. Epub 2015 Feb 17.

PMID:
25689146
15.

AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.

Di Paolo T, Grégoire L, Feuerbach D, Elbast W, Weiss M, Gomez-Mancilla B.

Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23. doi: 10.1016/j.parkreldis.2014.05.007. Epub 2014 May 22.

PMID:
25172125
16.

Decrease of mGluR5 receptor density goes parallel with changes in enkephalin and substance P immunoreactivity in Huntington's disease: a preliminary investigation in the postmortem human brain.

Gulyás B, Sovago J, Gomez-Mancilla B, Jia Z, Szigeti C, Gulya K, Schumacher M, Maguire RP, Gasparini F, Halldin C.

Brain Struct Funct. 2015 Sep;220(5):3043-51. doi: 10.1007/s00429-014-0812-y. Epub 2014 Jun 28.

PMID:
24969128
17.

Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias.

Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B.

Parkinsonism Relat Disord. 2014 Sep;20(9):947-56. doi: 10.1016/j.parkreldis.2014.05.003. Epub 2014 May 14. Review.

PMID:
24951359
18.

Translating molecular advances in fragile X syndrome into therapy: a review.

Hagerman RJ, Des-Portes V, Gasparini F, Jacquemont S, Gomez-Mancilla B.

J Clin Psychiatry. 2014 Apr;75(4):e294-307. doi: 10.4088/JCP.13r08714. Review.

PMID:
24813413
19.

Obsessive compulsive disorder and the glutamatergic system.

Kariuki-Nyuthe C, Gomez-Mancilla B, Stein DJ.

Curr Opin Psychiatry. 2014 Jan;27(1):32-7. doi: 10.1097/YCO.0000000000000017. Review.

PMID:
24270485
20.

Development of mavoglurant and its potential for the treatment of fragile X syndrome.

Gomez-Mancilla B, Berry-Kravis E, Hagerman R, von Raison F, Apostol G, Ufer M, Gasparini F, Jacquemont S.

Expert Opin Investig Drugs. 2014 Jan;23(1):125-34. doi: 10.1517/13543784.2014.857400. Epub 2013 Nov 20. Review.

PMID:
24251408
21.

Fragile X syndrome: a preclinical review on metabotropic glutamate receptor 5 (mGluR5) antagonists and drug development.

Pop AS, Gomez-Mancilla B, Neri G, Willemsen R, Gasparini F.

Psychopharmacology (Berl). 2014 Mar;231(6):1217-26. Review.

PMID:
24232444
22.

The challenges of clinical trials in fragile X syndrome.

Jacquemont S, Berry-Kravis E, Hagerman R, von Raison F, Gasparini F, Apostol G, Ufer M, Des Portes V, Gomez-Mancilla B.

Psychopharmacology (Berl). 2014 Mar;231(6):1237-50. doi: 10.1007/s00213-013-3289-0. Epub 2013 Oct 31. Review.

23.

Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks.

Gomez-Mancilla B, Brand R, Jürgens TP, Göbel H, Sommer C, Straube A, Evers S, Sommer M, Campos V, Kalkman HO, Hariry S, Pezous N, Johns D, Diener HC; BGG492 Study Group.

Cephalalgia. 2014 Feb;34(2):103-13. doi: 10.1177/0333102413499648. Epub 2013 Aug 20.

PMID:
23963355
24.

Metabotropic glutamate receptors for Parkinson's disease therapy.

Gasparini F, Di Paolo T, Gomez-Mancilla B.

Parkinsons Dis. 2013;2013:196028. doi: 10.1155/2013/196028. Epub 2013 Jun 19.

25.

Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.

Morin N, Morissette M, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.

Neuropharmacology. 2013 Oct;73:216-31. doi: 10.1016/j.neuropharm.2013.05.028. Epub 2013 Jun 10.

PMID:
23756168
26.

Molecular basis for prospective pharmacological treatment strategies in intellectual disability syndromes.

Verpelli C, Galimberti I, Gomez-Mancilla B, Sala C.

Dev Neurobiol. 2014 Feb;74(2):197-206. doi: 10.1002/dneu.22093. Epub 2013 Jul 19. Review.

27.

Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography.

Akkus F, Ametamey SM, Treyer V, Burger C, Johayem A, Umbricht D, Gomez Mancilla B, Sovago J, Buck A, Hasler G.

Proc Natl Acad Sci U S A. 2013 Jan 8;110(2):737-42. doi: 10.1073/pnas.1210984110. Epub 2012 Dec 17.

28.

Chronic administration of AFQ056/Mavoglurant restores social behaviour in Fmr1 knockout mice.

Gantois I, Pop AS, de Esch CE, Buijsen RA, Pooters T, Gomez-Mancilla B, Gasparini F, Oostra BA, D'Hooge R, Willemsen R.

Behav Brain Res. 2013 Feb 15;239:72-9. doi: 10.1016/j.bbr.2012.10.059. Epub 2012 Nov 6.

PMID:
23142366
29.

Increased metabotropic glutamate receptor subtype 5 availability in human brain after one night without sleep.

Hefti K, Holst SC, Sovago J, Bachmann V, Buck A, Ametamey SM, Scheidegger M, Berthold T, Gomez-Mancilla B, Seifritz E, Landolt HP.

Biol Psychiatry. 2013 Jan 15;73(2):161-8. doi: 10.1016/j.biopsych.2012.07.030. Epub 2012 Sep 7.

PMID:
22959709
30.

MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.

Morin N, Grégoire L, Morissette M, Desrayaud S, Gomez-Mancilla B, Gasparini F, Di Paolo T.

Neuropharmacology. 2013 Mar;66:355-64. doi: 10.1016/j.neuropharm.2012.07.036. Epub 2012 Jul 31.

PMID:
22884464
31.

Tweaking the social network.

Gomez-Mancilla B.

Sci Transl Med. 2012 Apr 25;4(131):131fs9. doi: 10.1126/scitranslmed.3004017.

PMID:
22539770
32.

Prerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.

Streffer JR, Grachev ID, Fitzer-Attas C, Gomez-Mancilla B, Boroojerdi B, Bronzova J, Ostrowitzki S, Victor SJ, Fontoura P, Alexander R.

Mov Disord. 2012 Apr 15;27(5):651-5. doi: 10.1002/mds.25017. Review.

PMID:
22508283
33.

The mGluR5 antagonist AFQ056 does not affect methylation and transcription of the mutant FMR1 gene in vitro.

Tabolacci E, Pirozzi F, Gomez-Mancilla B, Gasparini F, Neri G.

BMC Med Genet. 2012 Mar 7;13:13. doi: 10.1186/1471-2350-13-13.

34.

Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.

Brockmann K, Gröger A, Di Santo A, Liepelt I, Schulte C, Klose U, Maetzler W, Hauser AK, Hilker R, Gomez-Mancilla B, Berg D, Gasser T.

Mov Disord. 2011 Nov;26(13):2335-42. doi: 10.1002/mds.23991. Epub 2011 Oct 11.

PMID:
21989859
35.

AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.

Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Huber H, Morelli-Canelo M, Stamelou M, Ries V, Wolz M, Schneider C, Di Paolo T, Gasparini F, Hariry S, Vandemeulebroecke M, Abi-Saab W, Cooke K, Johns D, Gomez-Mancilla B.

Mov Disord. 2011 Jun;26(7):1243-50. doi: 10.1002/mds.23616. Epub 2011 Apr 11.

PMID:
21484867
36.

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.

Grégoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T.

Parkinsonism Relat Disord. 2011 May;17(4):270-6. doi: 10.1016/j.parkreldis.2011.01.008. Epub 2011 Feb 15.

PMID:
21315648
37.

Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056.

Jacquemont S, Curie A, des Portes V, Torrioli MG, Berry-Kravis E, Hagerman RJ, Ramos FJ, Cornish K, He Y, Paulding C, Neri G, Chen F, Hadjikhani N, Martinet D, Meyer J, Beckmann JS, Delange K, Brun A, Bussy G, Gasparini F, Hilse T, Floesser A, Branson J, Bilbe G, Johns D, Gomez-Mancilla B.

Sci Transl Med. 2011 Jan 5;3(64):64ra1. doi: 10.1126/scitranslmed.3001708.

38.

Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer's disease.

Sepulveda-Falla D, Matschke J, Bernreuther C, Hagel C, Puig B, Villegas A, Garcia G, Zea J, Gomez-Mancilla B, Ferrer I, Lopera F, Glatzel M.

Brain Pathol. 2011 Jul;21(4):452-63. doi: 10.1111/j.1750-3639.2010.00469.x. Epub 2011 Jan 27.

PMID:
21159009
39.

CSF-tau and CSF-Abeta(1-42) in posterior cortical atrophy.

Baumann TP, Duyar H, Sollberger M, Kuhle J, Regeniter A, Gomez-Mancilla B, Schmidtke K, Monsch AU.

Dement Geriatr Cogn Disord. 2010;29(6):530-3. doi: 10.1159/000314679. Epub 2010 Jul 1.

PMID:
20606434
40.

Changes of AMPA receptors in MPTP monkeys with levodopa-induced dyskinesias.

Ouattara B, Hoyer D, Grégoire L, Morissette M, Gasparini F, Gomez-Mancilla B, Di Paolo T.

Neuroscience. 2010 Jun 2;167(4):1160-7. doi: 10.1016/j.neuroscience.2010.03.022. Epub 2010 Mar 18.

PMID:
20303391
41.

Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys.

Ouattara B, Gasparini F, Morissette M, Grégoire L, Samadi P, Gomez-Mancilla B, Di Paolo T.

J Neurochem. 2010 May;113(3):715-24. doi: 10.1111/j.1471-4159.2010.06635.x. Epub 2010 Feb 1.

42.

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.

Morin N, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.

Neuropharmacology. 2010 Jun;58(7):981-6. doi: 10.1016/j.neuropharm.2009.12.024. Epub 2010 Jan 13.

PMID:
20074579
43.

Metabotropic glutamate receptor type 5 in levodopa-induced motor complications.

Ouattara B, Grégoire L, Morissette M, Gasparini F, Vranesic I, Bilbe G, Johns DR, Rajput A, Hornykiewicz O, Rajput AH, Gomez-Mancilla B, Di Paolo T.

Neurobiol Aging. 2011 Jul;32(7):1286-95. doi: 10.1016/j.neurobiolaging.2009.07.014. Epub 2009 Dec 29.

PMID:
20036444
44.

mGluR5 antagonists: discovery, characterization and drug development.

Gasparini F, Bilbe G, Gomez-Mancilla B, Spooren W.

Curr Opin Drug Discov Devel. 2008 Sep;11(5):655-65. Review.

PMID:
18729017
45.

Proteomic 2-D DIGE profiling of APP23 transgenic mice brain from pre-plaque and plaque phenotypes.

Guerreiro N, Staufenbiel M, Gomez-Mancilla B.

J Alzheimers Dis. 2008 Feb;13(1):17-30.

PMID:
18334753
46.
47.

Central nervous system drug development: an integrative biomarker approach toward individualized medicine.

Gomez-Mancilla B, Marrer E, Kehren J, Kinnunen A, Imbert G, Hillebrand R, Bergström M, Schmidt ME.

NeuroRx. 2005 Oct;2(4):683-95. Review.

48.

Pharmacogenetics and pharmacogenomics in drug development and regulatory decision making: report of the first FDA-PWG-PhRMA-DruSafe Workshop.

Lesko LJ, Salerno RA, Spear BB, Anderson DC, Anderson T, Brazell C, Collins J, Dorner A, Essayan D, Gomez-Mancilla B, Hackett J, Huang SM, Ide S, Killinger J, Leighton J, Mansfield E, Meyer R, Ryan SG, Schmith V, Shaw P, Sistare F, Watson M, Worobec A.

J Clin Pharmacol. 2003 Apr;43(4):342-58.

PMID:
12723455
49.

Elements of informed consent for pharmacogenetic research; perspective of the pharmacogenetics working group.

Anderson DC, Gomez-Mancilla B, Spear BB, Barnes DM, Cheeseman K, Shaw PM, Friedman J, McCarthy A, Brazell C, Ray SC, McHale D, Hashimoto L, Sandbrink R, Watson ML, Salerno RA, Cohen N, Lister CE; Pharmacogenetics Working Group.

Pharmacogenomics J. 2002;2(5):284-92. Review. No abstract available.

50.

Prospective study designs in outcomes research: the case of migraine.

Rothermich EA, Brod MI, Schonfeld WH, Rowland CR, Gomez-Mancilla B.

Pharmacoeconomics. 2002;20(11):715-25. Review.

PMID:
12201791

Supplemental Content

Loading ...
Support Center